{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:40:10Z","timestamp":1784907610631,"version":"3.55.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.amjmed.2018.10.013","type":"journal-article","created":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T13:53:08Z","timestamp":1540475588000},"page":"312-324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Canakinumab: Promises and Future in Cardiometabolic Diseases and Malignancy"],"prefix":"10.1016","volume":"132","author":[{"given":"Aneesh","family":"Dhorepatil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1754-1204","authenticated-orcid":false,"given":"Somedeb","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raktim K.","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Kondapaneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl J.","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2018.10.013_bib0001","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.cyto.2015.05.005","article-title":"IL-1 family members in the pathogenesis and treatment of metabolic disease: Focus on adipose tissue inflammation and insulin resistance","volume":"75","author":"Ballak","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0002","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart Disease and Stroke Statistics\u20132017 update: a report from the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.amjmed.2018.10.013_bib0003","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s11906-003-0085-y","article-title":"Cardiometabolic syndrome: pathophysiology and treatment","volume":"5","author":"Castro","year":"2003","journal-title":"Curr Hypertens Rep"},{"issue":"12","key":"10.1016\/j.amjmed.2018.10.013_bib0004","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med."},{"issue":"38","key":"10.1016\/j.amjmed.2018.10.013_bib0005","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1093\/eurheartj\/ehy286","article-title":"Post-ischaemic administration of the murine Canakinumab-surrogate antibody improves outcome in experimental stroke","volume":"39","author":"Liberale","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0006","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1016\/j.jacc.2018.03.002","article-title":"Anti-nflammatory therapy with canakinumab for the prevention and management of diabetes","volume":"71","author":"Everett","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0007","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/j.jacc.2018.03.490","article-title":"Inhibition of interleukin-1\u03b2 by canakinumab and cardiovascular outcomes in patients with chronic kidney disease","volume":"71","author":"Ridker","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0008","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","article-title":"Interleukin-1 in the pathogenesis and treatment of inflammatory diseases","volume":"117","author":"Dinarello","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0009","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0010","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fncel.2015.00018","article-title":"Interleukin-1 and acute brain injury","volume":"9","author":"Murray","year":"2015","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0011","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/cmi.2015.95","article-title":"Molecular mechanisms regulating NLRP3 inflammasome activation","volume":"13","author":"Jo","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0012","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11599820-000000000-00000","article-title":"Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1\u03b2 monoclonal antibody","volume":"51","author":"Chakraborty","year":"2012","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"10.1016\/j.amjmed.2018.10.013_bib0013","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/cpdd.455","article-title":"Bioequivalence of canakinumab injected subcutaneously via an autoinjector device or a prefilled safety syringe device in healthy subjects","volume":"7","author":"Anumolu","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0014","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-018-4119-x","article-title":"Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study [e-pub ahead of print]","author":"Sota","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0016","first-page":"179","article-title":"Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells","volume":"124","author":"Libby","year":"1986","journal-title":"Am J Pathol"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0017","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","article-title":"Endothelial cell dysfunction and the pathobiology of atherosclerosis","volume":"118","author":"Gimbrone","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0018","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/01.ATV.0000064374.15232.C3","article-title":"Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice","volume":"23","author":"Kirii","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0019","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1172\/JCI118476","article-title":"Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo: the role of platelet-derived growth factor","volume":"97","author":"Shimokawa","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0020","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/s41591-018-0124-5","article-title":"Interleukin-1\u03b2 has atheroprotective effects in advanced atherosclerotic lesions of mice","volume":"24","author":"Gomez","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0021","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.jacc.2016.07.768","article-title":"Arterial effects of canakinumab in patients with atherosclerosis and type 2 diabetes or glucose intolerance","volume":"68","author":"Choudhury","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0022","unstructured":"ClinicalTrials.gov; National Library of Medicine. Identifier NCT01731990. Safety, tolerability and efficacy of ACZ885 on leg artery structure in patients with peripheral artery disease. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01731990. Accessed September 19, 2018."},{"key":"10.1016\/j.amjmed.2018.10.013_bib0023","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/bcp.12905","article-title":"Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms","volume":"81","author":"Sahebkar","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0024","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-018-4119-x","article-title":"Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study [e-pub ahead of print]","author":"Sota","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0025","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/jama.286.3.327","article-title":"C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus","volume":"286","author":"Pradhan","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0026","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrd4275","article-title":"Targeting inflammation in the treatment of type 2 diabetes: time to start","volume":"13","author":"Donath","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0027","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1139\/cjpp-2017-0769","article-title":"Combined treatment with interleukin-1 and tumor necrosis factor-alpha antagonists improve type 2 diabetes in rats","volume":"96","author":"DiK","year":"2018","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0028","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa065213","article-title":"Interleukin-1\u2013receptor antagonist in type 2 diabetes mellitus","volume":"356","author":"Larsen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0029","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1463-1326.2012.01637.x","article-title":"Effect of anti-IL-1\u03b2 antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial","volume":"14","author":"Rissanen","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0030","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.diabet.2013.07.003","article-title":"Impact of interleukin-1\u03b2 antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: Results of secondary endpoints from a randomized, placebo-controlled trial","volume":"39","author":"Hensen","year":"2013","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0031","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1161\/CIRCULATIONAHA.112.122556","article-title":"Effects of interleukin-1 inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial","volume":"126","author":"Ridker","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0032","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1159\/000088261","article-title":"Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes","volume":"42","author":"Dominguez","year":"2005","journal-title":"J Vasc Res"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0033","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1001\/archinte.166.8.902","article-title":"Effects of etanercept in patients with the metabolic syndrome","volume":"166","author":"Bernstein","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0034","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/dc13-1527","article-title":"The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes","volume":"37","author":"Barzilay","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0035","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-152-6-201003160-00004","article-title":"The effects of salsalate on glycemic control in patients with type 2 diabetes","volume":"152","author":"Goldfine","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0036","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0037","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/569831","article-title":"Inflammatory factors and exercise in chronic kidney disease","volume":"2013","author":"Dungey","year":"2013","journal-title":"Int J Endocrinol"},{"issue":"9","key":"10.1016\/j.amjmed.2018.10.013_bib0038","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/nep.12785","article-title":"The NLRP3 inflammasome in kidney disease and autoimmunity","volume":"21","author":"Hutton","year":"2016","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0039","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1681\/ASN.2016040453","article-title":"IL-1 inhibition and vascular function in CKD","volume":"28","author":"Nowak","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0040","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1172\/JCI80007","article-title":"Immunity, inflammation, and cancer: an eternal fight between good and evil","volume":"125","author":"Shalapour","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0041","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1073\/pnas.0437939100","article-title":"IL-1 is required for tumor invasiveness and angiogenesis","volume":"100","author":"Voronov","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0042","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1479-5876-4-48","article-title":"Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment","volume":"4","author":"Lewis","year":"2006","journal-title":"J Transl Med"},{"issue":"10","key":"10.1016\/j.amjmed.2018.10.013_bib0043","doi-asserted-by":"crossref","first-page":"8163","DOI":"10.1002\/jcb.26813","article-title":"IL-1\u03b2 promotes the nuclear translocaiton of S100A4 protein in gastric cancer cells MGC803 and the cell's stem-like properties through PI3K pathway","volume":"119","author":"Yu","year":"2018","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0044","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.prp.2018.05.011","article-title":"IL-1\u03b2\/IL-6 network in the tumor microenvironment of human colorectal cancer","volume":"214","author":"Cui","year":"2018","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0045","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1097\/JTO.0b013e3181f387e4","article-title":"The role of inflammation in the pathogenesis of non-small cell lung cancer","volume":"5","author":"O'Callaghan","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0046","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0047","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1470-2045(14)70155-X","article-title":"MABp1, a first-in-class true human antibody targeting interleukin-1\u03b1 in refractory cancers: an open-label, phase 1 dose-escalation and expansion study","volume":"15","author":"Hong","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0048","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4065\/84.2.114","article-title":"Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component","volume":"84","author":"Lust","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.amjmed.2018.10.013_bib0049","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ahj.2013.03.018","article-title":"Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis","volume":"166","author":"Everett","year":"2013","journal-title":"Am Heart J"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934318310301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934318310301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:17:14Z","timestamp":1757582234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934318310301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0002934318310301"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2018.10.013","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Canakinumab: Promises and Future in Cardiometabolic Diseases and Malignancy","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2018.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}